Neuropathology is the branch of medicine that studies disease in the nervous system by examining tissue under a microscope and, increasingly, through molecular testing. It sits at the intersection of neurology, neurosurgery, and pathology, and its core task is straightforward: look at the brain, spinal cord, peripheral nerves, or muscle at the cellular level and figure out what went wrong. That examination can happen during surgery (a frozen section rushed to the pathologist while the patient is still on the operating table), after a biopsy, or at autopsy. Far from being a purely academic exercise, neuropathology shapes real-time treatment decisions, refines our understanding of why neurological diseases behave the way they do, and frequently reveals that the clinical diagnosis made during a patient’s life was incomplete or incorrect.
What a Neuropathologist Actually Does
A neuropathologist spends much of the day at a multi-headed microscope, reviewing thin slices of nervous-system tissue stained with dyes and antibodies that highlight specific proteins. The work falls roughly into two buckets. The first is surgical neuropathology: a neurosurgeon removes a brain tumor or a piece of epileptic cortex, and the neuropathologist determines what the lesion is, how aggressive it looks, and which molecular markers it carries. The second bucket is autopsy neuropathology, which includes examining the brains of people who died with dementia, movement disorders, or other neurological conditions. Brain banks, which collect and store donated brain tissue, are essential infrastructure for this work. The Seoul National University Hospital Dementia Brain Bank, for instance, has documented how often the diagnosis made during life actually matches what the tissue shows after death. The concordance rate varied sharply by disease: it was perfect for Huntington’s disease and progressive supranuclear palsy, roughly 86% for ALS, about 59% for Lewy body disease, and only around 42% for Alzheimer’s disease neuropathologic change compared to a clinical Alzheimer’s diagnosis.1PubMed Central. Current Status and Future Perspective of Seoul National University Hospital-Dementia Brain Bank with Concordance of Clinical and Neuropathological Diagnosis Those numbers are a reminder that clinical neurology, even with modern imaging, gets things wrong more often than most people realize, and that the microscope remains the final arbiter for many conditions.
Alzheimer’s Disease and Braak Staging
Alzheimer’s disease is the condition most people associate with neuropathology, and the field’s contribution here has been enormous. In 1991, Heiko Braak and Eva Braak examined brains from both demented and non-demented individuals and found that the neurofibrillary tangles characteristic of Alzheimer’s spread through the brain in a remarkably predictable sequence. Amyloid plaques, the other hallmark protein deposit, turned out to be too variable in their distribution to reliably mark disease stage. Tangles, by contrast, followed a six-stage pattern. The earliest changes appeared in the transentorhinal region of the temporal lobe, then spread into the entorhinal cortex and hippocampus, and finally engulfed the higher-order association cortex in advanced disease.2PubMed. Neuropathological stageing of Alzheimer-related changes This staging system has become one of the most widely used frameworks in all of neuropathology. The underlying process involves a hyperphosphorylated form of the tau protein accumulating inside specific types of neurons, and subsequent refinements have made it possible to perform Braak staging on standard paraffin-embedded sections using immunostaining, which is far more practical for routine diagnostic labs than the original thick-section silver-stain technique.3PubMed Central. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
What makes Braak staging so useful is that it tells you not just whether someone had Alzheimer’s pathology, but how far along it had progressed. Stages I and II can be found in cognitively normal middle-aged adults, which is one of the reasons Alzheimer’s is increasingly understood as a disease that begins decades before symptoms appear. Stages V and VI correspond to widespread cortical destruction and severe dementia. For researchers, this grading system provides a common language that makes it possible to compare findings across brain banks and clinical trials worldwide.
LATE and the Other Dementia You Have Not Heard Of
One of the most consequential discoveries in recent neuropathology has been that many elderly people diagnosed with Alzheimer’s disease during life actually have a different or additional pathology at autopsy. Limbic-predominant age-related TDP-43 encephalopathy, or LATE, involves deposits of the protein TDP-43 concentrated in the medial temporal lobe. It produces a slowly progressive memory-loss syndrome that looks clinically almost identical to Alzheimer’s disease.4PubMed Central. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy LATE pathology is detectable in more than a third of people over age 85 at autopsy and is robustly associated with dementia independent of other pathologies.5PubMed Central. Limbic-predominant age-related TDP-43 encephalopathy (LATE-NC): Co-pathologies and genetic risk factors provide clues about pathogenesis It frequently co-occurs with Alzheimer’s changes, which complicates the picture further. The existence of LATE helps explain why some anti-amyloid therapies that target Alzheimer’s plaques have had disappointing results in clinical trials: a meaningful slice of the patients enrolled probably had LATE as a contributor to their symptoms, and removing amyloid would not fix TDP-43 deposits.
Lewy Body Disease and Alpha-Synuclein
Parkinson’s disease and dementia with Lewy bodies are both caused by the abnormal accumulation of a protein called alpha-synuclein. Neuropathologists have long recognized Lewy bodies, the round protein clumps visible inside neurons, as the signature lesion. But more detailed research has shown that roughly 90% or more of alpha-synuclein aggregates in dementia with Lewy bodies are actually located at the presynapses, the tiny terminals where neurons communicate, in the form of very small deposits rather than the large classical Lewy bodies.6PubMed Central. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia The same presynaptic pathology has been demonstrated in Parkinson’s disease. Alongside these tiny presynaptic aggregates, the receiving end of the synapse, the dendritic spine, retracts, which suggests that the neuron is being starved of its normal chemical signals. This shift in understanding from big visible inclusions to widespread synaptic disruption has reshaped how researchers think about cognitive decline in these diseases.
ALS, Frontotemporal Dementia, and the TDP-43 Connection
Amyotrophic lateral sclerosis and frontotemporal dementia were once considered entirely separate diseases. ALS destroys motor neurons, causing progressive paralysis. Frontotemporal dementia erodes personality, language, or behavior. Neuropathology is what revealed their hidden kinship. The protein TDP-43, which normally lives in the cell nucleus, was identified as the major pathological protein in both sporadic ALS and the most common subtype of frontotemporal dementia. In affected cells, abnormal fragments of TDP-43 become tagged with ubiquitin, get hyperphosphorylated, and accumulate as clumps in the cytoplasm. The cell’s nucleus, meanwhile, loses its normal TDP-43 staining, suggesting that the protein is being pulled out of where it belongs.7PubMed Central. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia Mutations in the gene encoding TDP-43 have since been found in patients with both familial and sporadic ALS, cementing the link. The recognition of “TDP-43 proteinopathies” as a biochemical class of neurodegenerative disease was a neuropathological achievement that fundamentally changed how clinicians and researchers think about these conditions.
Cerebrovascular Disease and Amyloid Angiopathy
Stroke is often thought of as a sudden vascular event, but the brain’s blood vessels accumulate their own forms of chronic disease that neuropathologists are uniquely positioned to evaluate. Cerebral amyloid angiopathy, or CAA, involves the same amyloid-beta protein found in Alzheimer’s plaques, but deposited in the walls of blood vessels rather than in the brain tissue itself. Pathological evidence of CAA is detected in roughly half of all individuals over 70.8PubMed Central. Cerebral Amyloid Angiopathy and Blood-Brain Barrier Dysfunction The amyloid damages vessel walls, causes the blood-brain barrier to leak, and can lead to both hemorrhages and reduced blood flow. The clinical consequences span a wide range, from lobar brain bleeds and tiny cortical microbleeds to white-matter ischemic changes and inflammation of the vessel wall itself.9PubMed Central. Cerebral amyloid angiopathy: emerging concepts
What has become clear over the past decade is that CAA does not merely cause acute bleeds. It is also linked to brain atrophy in regions far from any hemorrhage and to progressive cognitive decline even when no new strokes occur, making it something that behaves like a neurodegenerative disease in its own right.10PubMed. Cerebral amyloid angiopathy as a cause of neurodegeneration This matters for patients on blood thinners: CAA-affected vessels are fragile, and anticoagulation increases bleeding risk in ways that standard vascular-risk models do not capture.
Brain Tumors and the Molecular Revolution
Few areas of neuropathology have changed as dramatically in recent years as brain tumor classification. Traditionally, a neuropathologist would look at a tumor under the microscope, assess how the cells appeared and how fast they were dividing, and assign a grade. That approach still matters, but molecular markers now carry at least equal weight. Gliomas, the most common primary brain tumors in adults, can be classified into five principal groups based on just three molecular markers: mutations in the IDH gene, codeletion of chromosome arms 1p and 19q, and mutations in the TERT promoter. These groups have different ages of onset, different survival times, and different underlying biology, implying distinct mechanisms of disease.11PubMed Central. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors Under the current WHO classification, molecular features can now affect not only the tumor’s classification but its grade as well.12PubMed Central. Updates on the WHO diagnosis of IDH-mutant glioma
For grade II gliomas specifically, molecular classification using IDH mutation, 1p/19q codeletion, and loss of the ATRX protein predicts patient outcomes more accurately than the traditional microscopic appearance alone.13PubMed Central. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas The practical consequence is that two tumors that look identical under the microscope may receive different diagnoses and treatment plans based on their molecular profiles.
Glioblastoma, the most aggressive primary brain tumor, has its own characteristic neuropathological features. The hallmark finding is pseudopalisading necrosis: zones of dead tissue surrounded by dense rings of tumor cells. These pseudopalisades are hypoxic, and the cells forming them are actively migrating away from areas where blood vessels have been blocked.14PubMed. ‘Pseudopalisading’ necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis Combined with rampant new blood-vessel growth (microvascular hyperplasia), these features make glioblastoma one of the most hypoxic and simultaneously most blood-vessel-rich tumors in the body.15Trends in Cancer. The glioblastoma microenvironment: morphology and niches
Chronic Traumatic Encephalopathy
CTE has received enormous public attention because of its association with contact sports, but it remains a diagnosis that can only be confirmed at autopsy. The defining feature is deposits of hyperphosphorylated tau protein as tangles in neurons and astrocytes, clustered around small blood vessels at the depths of the cortical grooves (sulci).16PubMed Central. The neuropathology of chronic traumatic encephalopathy That perivascular, sulcal-depth pattern is what distinguishes CTE from Alzheimer’s disease under the microscope. In Alzheimer’s, tau tangles spread diffusely through cortical layers; in CTE, the earliest deposits cluster around blood vessels at biomechanically vulnerable sites where the brain experiences the most shearing force during impacts.17PubMed Central. Tau Pathology in Chronic Traumatic Encephalopathy and Alzheimer’s Disease: Similarities and Differences After brain injury, hyperphosphorylated tau aggregates appear within a shorter time frame than they do in Alzheimer’s, consistent with the idea that trauma is directly triggering the pathology. Ongoing research aims to develop imaging biomarkers that could detect CTE during life, but for now the neuropathologist’s assessment remains the only definitive diagnostic tool.
Prion Diseases
Prion diseases, such as Creutzfeldt-Jakob disease, are among the most feared conditions a neuropathologist encounters. They are caused not by a virus or bacterium but by a misfolded form of a normal brain protein called PrP. Under the microscope, the tissue shows spongiform change, meaning the brain is riddled with tiny vacuoles that give it a sponge-like appearance, along with neuronal loss and overgrowth of astrocytes. In some cases, amyloid plaques composed of PrP protein are also present.18PubMed. Transmissible spongiform encephalopathy (Creutzfeldt-Jakob disease). Atypical clinical and pathological findings Since the 1990s, classification systems for sporadic CJD have been developed based on the specific pattern of these features: the nature and degree of spongiform vacuolation, the extent of neuronal loss and astrocyte proliferation, and the way misfolded PrP accumulates in different brain regions.19PubMed. Pathological spectrum of sporadic Creutzfeldt-Jakob disease Different subtypes of CJD have distinct clinical presentations and rates of progression, and the neuropathological subtype often explains why two patients with “the same disease” can look so different.
Epilepsy Surgery and Hippocampal Sclerosis
When seizure medications fail, surgery to remove the brain region generating seizures can be life-changing. Neuropathology plays a central role in this process. The most common finding in tissue removed from patients with drug-resistant temporal lobe epilepsy is hippocampal sclerosis, a pattern of selective neuronal loss and scarring in the hippocampus.20PubMed. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods Different patterns of cell loss within the hippocampus have been linked to different surgical outcomes, which is why the pathologist’s report is not just academic record-keeping but relevant to predicting whether the patient will remain seizure-free.
Beyond hippocampal sclerosis, a broad spectrum of malformations of cortical development can be identified in surgical specimens. Focal cortical dysplasias, areas where the brain’s cortex did not form properly during development, are a major cause of epilepsy in children and young adults. These are classified into types based on the specific structural abnormalities: Type I involves disrupted cortical layering, while Type II includes abnormal giant neurons or balloon cells.21PubMed Central. The clinico-pathological spectrum of Focal Cortical Dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission Milder forms of cortical malformation, including misplaced neurons in the white matter, can also be present.22PubMed. Malformations of cortical development and epilepsies: neuropathological findings with emphasis on focal cortical dysplasia Accurate classification matters because it informs the likelihood of seizure recurrence and guides decisions about further treatment.
Multiple Sclerosis Lesion Classification
Multiple sclerosis is an autoimmune disease that damages the myelin insulation around nerve fibers. Neuropathologists can classify MS lesions based on two features: inflammatory activity (whether immune cells are present) and demyelinating activity (whether myelin is actively being destroyed). The updated system distinguishes between active lesions, where immune cells are distributed throughout the lesion area; mixed active/inactive lesions, which have a quiet center but immune cells concentrated at the border; and inactive lesions, which are largely depleted of immune cells.23PubMed. An updated histological classification system for multiple sclerosis lesions The mixed active/inactive type, sometimes called a “smoldering” lesion, has attracted particular research interest because it may represent a slowly expanding process of tissue injury that continues even when the patient appears clinically stable. This classification is shaping how researchers evaluate new therapies, since a drug that prevents new active lesions might still leave smoldering lesions untouched.
Infections of the Nervous System
Infectious diseases of the brain and spinal cord produce a wide variety of tissue reactions, and the pattern of inflammation often points toward the category of pathogen before culture or molecular tests return results. Viral encephalitis tends to produce clusters of activated microglia (the brain’s resident immune cells), microglial nodules, and the process of neuronophagia, where immune cells surround and consume a dying neuron. Granulomatous inflammation with giant cells is more characteristic of tuberculosis and fungal or parasitic infections. Parasitic infections frequently bring eosinophils, a type of white blood cell rarely prominent in other central nervous system conditions. Some infections, including syphilis and varicella-zoster virus, can cause vasculitis, inflammation of the blood vessel walls that can lead to stroke.24PubMed Central. What every neuropathologist needs to know: Update on neuro infectious disease workups and consultation resources Recognizing these tissue patterns quickly can be the difference between starting the right antibiotic or antifungal and losing critical time.
Peripheral Nerve Biopsy
Neuropathology extends beyond the brain. Nerve biopsy, typically of the sural nerve in the lower leg, remains a valuable diagnostic tool for certain peripheral neuropathies. Its main indications today include suspected vasculitis affecting the nerves, amyloid deposits in nerve tissue, unusual presentations of inflammatory neuropathy, and hereditary neuropathies that cannot be pinned down by genetic testing alone.25PubMed Central. Processing of nerve biopsies: a practical guide for neuropathologists Because nerve biopsy is invasive and causes permanent numbness in the area supplied by the removed nerve, it is reserved for cases where less invasive tests have not provided a clear answer. When it is performed, the tissue goes through specialized processing that includes electron microscopy and teased-fiber preparations, techniques that are more elaborate than standard surgical pathology and require specific expertise.
Artificial Intelligence in Neuropathology
The field is changing fast. Deep learning algorithms applied to digitized whole-slide images of brain tumors can now achieve neuropathologist-level accuracy in predicting molecular markers like IDH mutation and 1p/19q codeletion directly from the tissue appearance, without running the actual molecular test.26PubMed Central. AI-Powered Histology for Molecular Profiling in Brain Tumors: Toward Smart Diagnostics from Tissue Some of these tools are being extended to frozen sections examined during surgery, raising the possibility of real-time molecular predictions while the patient is still in the operating room. Beyond tumors, AI systems have demonstrated high accuracy for brain tumor classification, moderate accuracy for grading neurodegenerative diseases, and emerging usefulness in assessing demyelinating conditions like MS.27Surgical and Experimental Pathology. Digital pathology and artificial intelligence in neuropathological diagnosis: a comprehensive review of current applications, challenges, and future directions
The enthusiasm comes with caveats. AI models trained on slides from one institution often perform worse on slides from another, because differences in tissue processing, staining protocols, and scanner hardware create subtle visual shifts that confuse algorithms. Regulatory approval for clinical use lags behind the research papers. And for neurodegenerative diseases, where subtle regional differences in protein deposition carry diagnostic weight, AI still trails experienced human neuropathologists in the kinds of integrative judgments required. The technology is best understood as an increasingly powerful assistant rather than a replacement, one that could eventually make expert-level neuropathological assessment available in hospitals that currently lack a specialist.